CL2019002897A1 - Tratamiento para el asma con anticuerpo anti-tslp. - Google Patents

Tratamiento para el asma con anticuerpo anti-tslp.

Info

Publication number
CL2019002897A1
CL2019002897A1 CL2019002897A CL2019002897A CL2019002897A1 CL 2019002897 A1 CL2019002897 A1 CL 2019002897A1 CL 2019002897 A CL2019002897 A CL 2019002897A CL 2019002897 A CL2019002897 A CL 2019002897A CL 2019002897 A1 CL2019002897 A1 CL 2019002897A1
Authority
CL
Chile
Prior art keywords
asthma
antibody treatment
tslp antibody
tslp
lymphopoyetin
Prior art date
Application number
CL2019002897A
Other languages
English (en)
Spanish (es)
Inventor
Jane R Parnes
Janet Griffiths
Original Assignee
Amgen Inc
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Medimmune Llc filed Critical Amgen Inc
Publication of CL2019002897A1 publication Critical patent/CL2019002897A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2019002897A 2017-04-12 2019-10-11 Tratamiento para el asma con anticuerpo anti-tslp. CL2019002897A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484864P 2017-04-12 2017-04-12
US201762553477P 2017-09-01 2017-09-01
US201762553575P 2017-09-01 2017-09-01

Publications (1)

Publication Number Publication Date
CL2019002897A1 true CL2019002897A1 (es) 2020-03-06

Family

ID=62092313

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002897A CL2019002897A1 (es) 2017-04-12 2019-10-11 Tratamiento para el asma con anticuerpo anti-tslp.

Country Status (22)

Country Link
US (3) US10828365B2 (enExample)
EP (1) EP3609917A1 (enExample)
JP (4) JP7330896B2 (enExample)
KR (2) KR102666879B1 (enExample)
CN (1) CN110573525A (enExample)
AU (2) AU2018253118B2 (enExample)
BR (1) BR112019021482A2 (enExample)
CA (1) CA3059364A1 (enExample)
CL (1) CL2019002897A1 (enExample)
CO (1) CO2019011462A2 (enExample)
IL (1) IL269791B (enExample)
JO (1) JOP20190243B1 (enExample)
MX (1) MX2019012158A (enExample)
MY (1) MY207509A (enExample)
PE (1) PE20200484A1 (enExample)
PH (1) PH12019502331A1 (enExample)
SG (1) SG11201909322VA (enExample)
TN (1) TN2019000289A1 (enExample)
TW (2) TWI856945B (enExample)
UA (1) UA130334C2 (enExample)
UY (1) UY37676A (enExample)
WO (1) WO2018191479A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3842457A1 (en) * 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
TWI917325B (zh) * 2019-06-04 2026-03-11 大陸商江蘇恆瑞醫藥股份有限公司 能結合胸腺基質淋巴細胞生成素的抗體及其應用
US12435131B2 (en) 2019-07-11 2025-10-07 Tavotek Biotherapeutics (Hong Kong) Limited Agents that interfere with thymic stromal lymphopoietin (TSLP)-receptor signaling
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合ｔｓｌｐ及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
CN114887053B (zh) * 2019-11-29 2026-04-24 康诺亚生物医药科技（成都）有限公司 一种tslp相关病症治疗剂的开发和应用
EP4047019A4 (en) * 2019-12-13 2023-11-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-tslp antibody and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CR20220457A (es) * 2020-02-13 2023-01-09 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y métodos de tratamiento de una enfermedad inflamatoria
EP4103605A1 (en) * 2020-02-13 2022-12-21 Amgen Inc. Treatment of atopic dermatitis with anti-tslp antibody
MX2022010120A (es) * 2020-02-18 2022-09-05 Amgen Inc Formulaciones de anticuerpos anti-tslp humanos y metodos de uso de los mismos.
CN113388035B (zh) * 2020-03-13 2026-02-27 迈威(上海)生物科技股份有限公司 特异性针对人tslp的抗体及其应用
WO2022117079A1 (zh) * 2020-12-03 2022-06-09 江苏恒瑞医药股份有限公司 结合胸腺基质淋巴细胞生成素的抗体及其应用
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
CN114853888B (zh) * 2021-02-05 2023-11-03 上海洛启生物医药技术有限公司 抗tslp纳米抗体及其应用
TWI915520B (zh) * 2021-03-03 2026-02-21 大陸商正大天晴藥業集團股份有限公司 含抗tslp抗體的藥物組合物
CR20230533A (es) * 2021-04-19 2024-04-05 Medimmune Ltd Un fab anti-tslp con estabilidad mejorada
KR20230175245A (ko) 2021-04-23 2023-12-29 암젠 인크 변형된 항-tslp 항체
US20240190951A1 (en) 2021-04-23 2024-06-13 Amgen Inc. Anti-tslp antibody compositions and uses thereof
CA3217029A1 (en) * 2021-05-30 2022-12-08 Biolojic Design Ltd. Engineered dual binding antibodies and uses thereof
CN113683694B (zh) 2021-09-03 2022-05-13 江苏荃信生物医药股份有限公司 一种抗人tslp单克隆抗体及其应用
CN117209604B (zh) * 2021-12-02 2024-03-22 北京东方百泰生物科技股份有限公司 一种抗tslp的单克隆抗体、其抗原结合片段及其应用
CN117327176B (zh) * 2022-06-24 2026-08-04 南京融捷康生物科技有限公司 一种抗tslp的单域抗体及其用途
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
TW202426485A (zh) 2022-10-26 2024-07-01 美商安進公司 抗ｔｓｌｐ抗體組成物及其用途
IL326774A (en) * 2023-08-25 2026-04-01 Proteologix Us Inc Anti-tslp antibody constructs and uses thereof
AR133647A1 (es) 2023-08-25 2025-10-22 Proteologix Us Inc Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos
CN117551195B (zh) * 2024-01-12 2024-04-09 杭州畅溪制药有限公司 靶向tslp的vhh纳米抗体及其应用
WO2025179220A1 (en) * 2024-02-22 2025-08-28 Flagship Pioneering Innovations Vi, Llc Dosing of antigen binding molecules targeting thymic stromal lymphopoietin (tslp)
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026076381A1 (en) * 2024-10-04 2026-04-09 Prana Therapies, Inc. Il-4r and tslp inhibitors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
US9100245B1 (en) 2012-02-08 2015-08-04 Amazon Technologies, Inc. Identifying protected media files
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers
JP6715767B2 (ja) * 2013-10-23 2020-07-01 ジェネンテック， インコーポレイテッド 好酸球性疾患の診断及び治療方法
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
CN107428828A (zh) * 2015-03-11 2017-12-01 葛兰素史密斯克莱知识产权发展有限公司 Tslp结合蛋白
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody

Also Published As

Publication number Publication date
IL269791B (en) 2022-07-01
TWI856945B (zh) 2024-10-01
TN2019000289A1 (en) 2021-05-07
JP2023099233A (ja) 2023-07-11
TW201838652A (zh) 2018-11-01
KR20190140956A (ko) 2019-12-20
TW202523688A (zh) 2025-06-16
UA130334C2 (uk) 2026-01-28
JOP20190243B1 (ar) 2024-12-22
AU2018253118A1 (en) 2019-10-24
US10828365B2 (en) 2020-11-10
KR102666879B1 (ko) 2024-05-23
KR20240070727A (ko) 2024-05-21
BR112019021482A2 (pt) 2020-05-12
JP2020516647A (ja) 2020-06-11
JP2025170430A (ja) 2025-11-18
US20250032608A1 (en) 2025-01-30
PH12019502331A1 (en) 2020-09-28
CN110573525A (zh) 2019-12-13
JP2024150751A (ja) 2024-10-23
PE20200484A1 (es) 2020-03-03
JP7330896B2 (ja) 2023-08-22
JOP20190243A1 (ar) 2019-10-13
MY207509A (en) 2025-02-28
CA3059364A1 (en) 2018-10-18
MX2019012158A (es) 2019-12-16
CO2019011462A2 (es) 2019-10-31
US20180296669A1 (en) 2018-10-18
JP7894910B2 (ja) 2026-07-24
US20210052726A1 (en) 2021-02-25
IL269791A (en) 2019-11-28
UY37676A (es) 2018-10-31
EP3609917A1 (en) 2020-02-19
WO2018191479A1 (en) 2018-10-18
AU2025204735A1 (en) 2025-07-17
AU2018253118B2 (en) 2025-04-10
SG11201909322VA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CO2019011462A2 (es) Tratamiento para el asma con anticuerpo anti-tslp
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
BR112019012342A2 (pt) anticorpos il-11
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MX2017000116A (es) Moleculas basadas en il-15 y metodos para su uso.
CO2017000300A2 (es) Moléculas con especificidad para cd45 y cd79
BR112018012839A2 (pt) composições endofíticas e métodos para melhoramento de traços de plantas em plantas de importância agronômica
MX2018010445A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2015012437A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2019002323A1 (es) Anticuerpo dirigido a il-13ra2 y su uso.
CO2023015915A2 (es) Anticuerpos anti-ccr8
MX379312B (es) Anticuerpos especificos para fcrn.
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.